MétaCan
Menu
← Back to cohort
Record W2914013737 · doi:10.1093/ecco-jcc/jjy222.537

P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease

2019· article· en· W2914013737 on OpenAlexaff
Parambir S. Dulai, Aurélien Amiot, Laurent Peyrin‐Biroulet, Siddharth Singh, Mélanie Serrero, Vipul Jairath, Jérôme Filippi, Benjamin Pariente, Edward V. Loftus, Xavier Roblin, Sunanda V. Kane, Anthony Buisson, Corey A. Siegel, Yoram Bouhnik, William J. Sandborn, Karen Lasch, Maria Rosario, Brian G. Feagan, Daniela Bojic, Caroline Trang-Poisson, Bo Shen, Romain Altwegg, B E Sands, J F Colombel, Franck Carbonnel, Matthew Bohm, David Hudesman, Anne Bourrier, Dana J. Lukin

Bibliographic record

VenueJournal of Crohn s and Colitis · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsWestern University
Fundersnot available
KeywordsCohortVedolizumabMedicineInternal medicineCohort studyDiseaseSurgeryCrohn's disease

Abstract

fetched live from OpenAlex

We previously created and validated a clinical decision support tool (CDST) for predicting response to vedolizumab (VDZ) in Crohn’s disease (CD). We now aim to further validate this tool in an additional CD cohort and assess its performance for predicting other health outcomes. Using GEMINI II data, we explored correlations between VDZ exposure and onset of action across CDST-predicted probability of response groups (low, intermediate, high). The operating properties of the CDST for prediction of clinical remission and onset of action in the GETAID VDZ cohort were evaluated. In the GETAID and VICTORY cohorts, response to dose optimisation was assessed, and in the VICTORY cohort, we assessed the ability of the CDST to predict risk of surgery while on active therapy. A linear relationship was observed between CDST-predicted probability of response groups, VDZ exposure, onset of action, and efficacy in the GEMINI cohort for Week 2 through Week 52 (p < 0.001). In the GETAID cohort, the CDST predicted clinical remission at Week 14 (AUC 0.68), and a significant difference in speed of onset of action was observed between low- and intermediate–high-probability groups (p = 0.04). In both the GETAID and VICTORY cohorts, only patients in the low-probability group significantly benefited from shortening of VDZ intervals to Q4 weeks for non-response. In the GETAID cohort, a single infusion at Week 10 for patients in the low-probability group overcame differences in speed of onset of action seen between this group and the intermediate–high-probability group. In the VICTORY cohort, the CDST predicted a 2-fold increase in risk for surgery over 12 months of VDZ therapy among low–intermediate-probability patients compared with high-probability patients (HR 2.06, 95% CI 1.33–3.21). The CD VDZ CDST demonstrated good performance during external validation in the GETAID cohort. This tool was able to prognosticate VDZ exposure-efficacy relationships and speed of onset of action, identify patients who would most benefit from interval shortening for lack of response, and stratify patients at greatest risk for surgery while on active therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.010
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.015

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.010
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.268
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and Colitis→Same topicInflammatory Bowel Disease→French-language works237,207→